临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1887069-10-4

Gamcemetinib (CC-99677)

CAS号:1887069-10-4
分子式: C22H20ClN5O3S 分子量: 469.95
产品形式: free base
研发状态: Completed
研发用途: Healthy Volunteers
研究机构: Bristol-Myers Squibb
研发日期: May 12 2022
研发阶段: Phase 1
Gamcemetinib (CC-99677,BMS-986371) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) (MAPKAPK2 (MK2)) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM).

CAS: 188062-50-2

Abacavir sulfate

中文名称:硫酸阿巴卡韦
CAS号:188062-50-2
分子式: C14H18N6O.1/2H2SO4 分子量: 335.35
产品形式: Sulfate
研发状态: Completed
研发用途: HIV-1 Infection
研究机构: ANRS Emerging Infectious Diseases; ViiV Healthcare
研发日期: February 10 2020
研发阶段: Not Applicable
Abacavir (1592U89) is a commonly used nucleoside analogue with potent antiviral activity against HIV-1.

CAS: 1876467-74-1

Elimusertib (BAY-1895344)

CAS号:1876467-74-1
分子式: C20H21N7O 分子量: 375.43
产品形式: Free Base
研发状态: Active not recruiting
研发用途: Recurrent Alveolar Rhabdomyosarcoma; Recurrent Ewing Sarcoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Refractory Alveolar Rhabdomyosarcoma; Refractory Ewing Sarcoma; Refractory Lymphoma; Refractory Malignant Solid Neoplasm
研究机构: National Cancer Institute (NCI)
研发日期: December 22 2021
研发阶段: Phase 1 : Phase 2
Elimusertib (BAY-1895344) is a very potent and highly selective ATR (ataxia telangiectasia and Rad3-related) inhibitor with IC50 of 7 nM. Elimusertib potently inhibits proliferation of a broad spectrum of human tumor cell lines with median IC50 of 78 nM.

CAS: 187235-37-6

Pretomanid (PA-824)

中文名称:(S)-6,7-二氢-2-硝基-6-[[4-(三氟甲氧基)苯基]甲氧基]-5H-咪唑并[2,1-B][1,3]恶嗪
CAS号:187235-37-6
分子式: C14H12F3N3O5 分子量: 359.26
产品形式: free base
研发状态: Completed
研发用途: Pulmonary Tuberculosis
研究机构: Global Alliance for TB Drug Development
研发日期: Mar-15
研发阶段: Phase 3
PA-824 is an anti-tuberculosis drug for tuberculosis with MIC less than 2.8 μM.Phase 2.

CAS: 187164-19-8

Luliconazole

中文名称:卢立康唑
CAS号:187164-19-8
分子式: C14H9Cl2N3S2 分子量: 354.28
产品形式: free base
研发状态: Active not recruiting
研发用途: Onychomycosis of Toenail
研究机构: SATO Pharmaceutical Co. Ltd.
研发日期: September 13 2021
研发阶段: Phase 1
Luliconazole(NND 502) is a broad-spectrum antifungal drug.

CAS: 1869912-40-2

AZD-5153 6-hydroxy-2-naphthoic acid

中文名称:AZD5153结晶体(API形式)
CAS号:1869912-40-2
分子式: C25H33N7O3.C11H8O3 分子量: 667.75
产品形式: free base
研发状态: Completed
研发用途: Malignant Solid Tumors; Lymphoma; Ovarian Cancer; Breast Cancer; Pancreatic Cancer; Prostate Cancer
研究机构: AstraZeneca
研发日期: June 30 2017
研发阶段: Phase 1
AZD-5153 6-hydroxy-2-naphthoic acid (HNT salt) is a potent, selective, and orally available BET/BRD4 bromodomain inhibitor with pKi of 8.3 for BRD4. AZD-5153 inhibits the expression of Nuclear receptor binding SET domain protein 3 (NSD3) target genes. NSD3, via H3K36me2, acts as an epigenetic deregulator to facilitate the expression of oncogenesis-promoting genes.